Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.

Autor:	Bourbeau B; American Society of Clinical Oncology, Alexandria, VA., Lyman GH; Fred Hutchinson Cancer Center, Seattle, WA.; University of Washington, Seattle, WA., Lei XJ; American Society of Clinical Oncology, Alexandria, VA., Jones L; Cancer Patient, Survivor, and Patient Advocate, Arlington, VA., Rosenthal J; American Society of Clinical Oncology, Alexandria, VA., Kozlik MM; American Society of Clinical Oncology, Alexandria, VA., Oettel KR; Gundersen Health System, La Crosse, WI., Tinger A; Bassett Cancer Institute, Cooperstown, NY., Page R; The Center for Cancer and Blood Disorders, Fort Worth, TX.
Jazyk:	angličtina
Zdroj:	JCO oncology practice [JCO Oncol Pract] 2023 Jul; Vol. 19 (7), pp. 516-522. Date of Electronic Publication: 2023 Apr 21.
DOI:	10.1200/OP.22.00618
Abstrakt:	Purpose: Biosimilars offer increased patient choice and potential cost-savings, compared with originator biologics. We studied 3 years of prescribed biologics among US physician practices to determine the relationship of practice type and payment source to oncology biosimilar use. Methods: We acquired biologic utilization data from 38 practices participating in PracticeNET. We focused on six biologics (bevacizumab, epoetin alfa, filgrastim, pegfilgrastim, rituximab, and trastuzumab) for the period from 2019 to 2021. We complemented our quantitative analysis with a survey of PracticeNET participants (prescribers and practice leaders) to reveal potential motivators and barriers to biosimilar use. We implemented logistic regression to evaluate the biosimilar use for each biologic, with covariates including time, practice type, and payment source, and accounted for clusters of practices. Results: Use of biosimilars increased over the 3-year period, reaching between 51% and 80% of administered doses by the fourth quarter of 2021, depending on the biologic. Biosimilar use varied by practice, with independent physician practices having higher use of biosimilars for epoetin alfa, filgrastim, rituximab, and trastuzumab. Compared with commercial health plans, Medicaid plans had lower biosimilar use for four biologics; traditional Medicare had lower use for five biologics. The average cost per dose decreased between 24% and 41%, dependent on the biologic. Conclusion: Biosimilars have, through increased use, lowered the average cost per dose of the studied biologics. Biosimilar use differed by originator biologic, practice type, and payment source. There remains further opportunity for increases in biosimilar use among certain practices and payers.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu